Uses of Pamidia 90mg/6ml

Pills Pamidia 90mg belongs to the group of pain relievers and fever reducers. Pamidia's main ingredient is Disodium Pamidronate 90mg/6ml, prepared in the form of a solution for intravenous infusion The following is information about uses, doses and precautions when using Pamidia.

Pamidia is indicated for use in the treatment of pathological conditions due to increased bone resorption of osteoclasts:
Hypercalcemia due to tumor pathology; Bone resorption and bone pain in patients with bone metastases due to breast cancer or bone marrow pain; Have Paget's disease of bone. Do not use the drug in people with hypersensitivity to pamidronate or to bisphosphonates.

Pamidia 90mg drug is used by injection. The dose of the drug will be adjusted according to the disease condition and the purpose of treatment. Specifically:
Use in case of hypercalcemia due to tumor disease: Patients need to be rehydrated and electrolytes with isotonic saline solution before or during treatment. The total dose of Di-Sodium Pamidronate for a course of treatment depends on the patient's baseline serum calcium. Use in cases of bone damage in myeloma: The recommended dose is 90mg every 4 weeks of treatment. Use in cases of osteolytic lesions and bone pain in osteolytic metastases of breast cancer patients: The recommended dose is 90mg every 4 weeks. Patients receiving chemotherapy if needed also use this dose every 3 weeks. Use in case of Paget's disease of bone: The total recommended dose of pamidronate is 180mg in 1 course of treatment, divided into 6 doses of 30mg 1 week or divided into 3 doses of 60mg administered every other week. In case of using a dose of 60mg, an additional dose of 30mg can be used at the beginning of treatment, but the total dose is only allowed to be 210mg. Each dose of 30 mg or 60 mg should be diluted with 125 or 250 ml of 0.9% NaCl solution and the infusion rate should not exceed 60 mg/hour, equivalent to 1 mg/min. The dose levels listed above or the dose increase will have to be dependent on the severity of the patient's illness, or the maximum dose level is 360 mg, divided into 60 mg doses that may be repeated after 6 months until the disease is in remission. decrease and when the disease recurs. Used in patients with renal failure, no dose adjustment is required. However, the dose should not exceed an infusion rate of 20 mg/hour in patients with renal impairment. Use in patients with hepatic impairment: Patients with hepatic impairment had higher mean AUC and Cmax values ​​than patients with normal liver function, however, this difference was not clinically significant. This is the reason that no dose adjustment is needed in patients with mild to moderate hepatic impairment.

Side effects with systemic signs: Commonly fever and flu-like symptoms are sometimes accompanied by malaise, chills, fatigue, hot flushes; Side effects are local reactions: Common injection site reactions such as pain, redness, swelling, stiffness, phlebitis, thrombophlebitis; Side effects on the musculoskeletal system: Common is transient bone pain, arthralgia, myalgia, body aches; Uncommon is muscle spasticity; Gastrointestinal side effects: Common is nausea or vomiting; Uncommon is anorexia, abdominal pain, diarrhea, constipation, digestive disorders; Very rarely is gastritis; Side effects with the central nervous system: Common is headache; Uncommon are symptomatic hypocalcemia, agitation, confusion, dizziness, insomnia, somnolence, lethargy; Very rarely convulsions, hallucinations; Side effects with blood: Common is lymphocytopenia; Uncommon is anemia, leukopenia; Very rarely is thrombocytopenia.

Serum electrolytes, serum calcium and phosphate should be monitored from the start of treatment with pamidronate; Patients who have undergone thyroid surgery may be prone to hypocalcemia due to hypoparathyroidism; Patients taking pamidronate continuously for a long time, especially those with kidney disease or at risk of renal failure (such as patients with multiple myeloma and/or tumor-induced hypercalcemia) should have periodic evaluation for laboratory tests. standard trial and clinical indices of renal function because decreased renal function (including renal failure) has been observed during long-term treatment with pamidronate in patients with multiple myeloma; There is no clear recommendation for the use of Di-Sodium pamidronate in patients with severe hepatic impairment; There is no experience with pamidronate in hemodialysis patients; The drug should not be used in pregnant women, unless there is life-threatening hypercalcemia; The drug should not be used by women who are breastfeeding; During the infusion of pamidronate, the patient may become somnolent and/or dizzy, so do not drive or operate machinery.

Pamidronate has been taken at the same time as conventional anticancer drugs without any interaction. Pamidronate has been used in combination with calcitonin in patients with severe hypercalcemia, producing a synergistic effect that results in a more rapid decrease in serum calcium.
Pamidronate binds to bone, so could theoretically affect bone scintigraphy results.